Fosbretabulin disodium

产品说明书

Print
Chemical Structure| 168555-66-6 同义名 : 康普瑞汀A4磷酸二钠 ;Combretastatin A4 disodium phosphate;CA 4P;CRC 87-09;Combrestatin A4;Combrestatin A4 3'-O-Phosphate (sodium salt);CA 4DP
CAS号 : 168555-66-6
货号 : A116116
分子式 : C18H19Na2O8P
纯度 : 99%+
分子量 : 440.292
MDL号 : MFCD00943911
存储条件：

Pure form Inert atmosphere,Store in freezer, under -20°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 4 mg/mL(9.08 mM)
动物实验配方：
生物活性
描述 Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent and is a proagent of Combretastatin A4, specifically targeting endothelial cells. It induces the regression of nascent tumor neovessels, diminishes tumor blood flow, and leads to central tumor necrosis[1].[3].
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
HeLa cells Proliferation assay Antiproliferative activity against human HeLa cells by sulforhodamine B assay, IC50=0.0047 μM 20973488
rat A10 cells Function assay Inhibition of microtubule depolymerization in rat A10 cells assessed as reorganization of interphase microtubule network by indirect immunofluorescence technique, EC50=0.007 μM 20973488
SKOV3 cells Proliferation assay Antiproliferative activity against human SKOV3 cells by sulforhodamine B assay, IC50=0.0045 μM 20973488
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00507429 Anaplastic Thyroid Cancer Phase 2 Phase 3 Terminated(Low rate of subject... 展开 >> accrual) 收起 << - -
NCT00395434 Tumors Phase 1 Completed - United Kingdom ... 展开 >> Mount Vernon Hospital Northwood, Middlesex, United Kingdom, HA6 2RN Royal Marsden Hospital Sutton, Surrey, United Kingdom, SM2 5PT 收起 <<
NCT00653939 Tumors Phase 2 Completed - United States, California ... 展开 >> Southbay Oncology Hematology Campbell, California, United States, 95008 Pacific Coast Hematology and Oncology Medical Group Fountain Valley, California, United States, 92708 UCLA Division of Hematology and Oncology Los Angeles, California, United States, 90095 Bay Area Cancer Research Group, LLC Pleasant Hill, California, United States, 94523 United States, Florida Boca Raton Comprehensive Cancer Center Boca Raton, Florida, United States, 21020 United States, Kentucky Kentuckiana Cancer Institute Louisville, Kentucky, United States, 40202 United States, Massachusetts Lahey Clinic Medical Center Burlington, Massachusetts, United States, 01805 United States, New Jersey The Center for Cancer and Hematologic Disease Cherry Hill, New Jersey, United States, 08003 United States, New Mexico San Juan Oncology Associates Farmington, New Mexico, United States, 87401 United States, Ohio Gabrail Cancer Center Canton, Ohio, United States, 44718 The Mark H. Zangmeister Center Columbus, Ohio, United States, 43219 Signal Point Clinical Research Middletown, Ohio, United States, 45042 United States, Virginia Blueridge Cancer Care Salem, Virginia, United States, 24153 United States, Washington Northwest Medical Specialties Tacoma, Washington, United States, 98405 United States, West Virginia Mary Babb Randolph Cancer Center-Clinical Trials Unit Morgantown, West Virginia, United States, 26506 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.27mL

0.45mL

0.23mL

11.36mL

2.27mL

1.14mL

22.71mL

4.54mL

2.27mL
参考文献

[1]Shen CH, et, al. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol. 2010 Aug;160(8):2008-27.

[2]Pettit GR, et, al. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41. J Med Chem. 2005 Jun 16;48(12):4087-99.

[3]Tozer GM, et, al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999 Apr 1;59(7):1626-34.